Zhang, Weiruo
Li, Irene
Reticker-Flynn, Nathan E.
Good, Zinaida http://orcid.org/0000-0003-2343-5771
Chang, Serena
Samusik, Nikolay
Saumyaa, Saumyaa
Li, Yuanyuan
Zhou, Xin http://orcid.org/0000-0003-4015-4787
Liang, Rachel
Kong, Christina S.
Le, Quynh-Thu
Gentles, Andrew J. http://orcid.org/0000-0002-0941-9858
Sunwoo, John B. http://orcid.org/0000-0002-8393-4196
Nolan, Garry P. http://orcid.org/0000-0002-8862-9043
Engleman, Edgar G.
Plevritis, Sylvia K.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U54 CA209971, U54 CA209971, U54 CA209971, U54 CA209971, U54 CA209971, U54 CA209971, U54 CA209971, U54 CA209971, U54 CA209971, U54 CA209971, U54 CA209971, U54 CA209971, U54 CA209971, U54 CA209971, U54 CA209971, U54 CA209971)
Parker Institute for Cancer Immunotherapy at San Francisco, CA, USA, and Stanford Cancer Institute, CA, USA
Tobacco-Related Disease Research Program (T31IP1598, T31IP1598)
Article History
Received: 14 April 2021
Accepted: 15 April 2022
First Online: 2 June 2022
Competing interests
: Z.G. is an inventor on two patent applications and an investor in Boom Capital Ventures, and a consultant for Mubadala Ventures, GLG and Atheneum Partners. Q.-T.L. has received grants from Varian and serves as a consultant for Nanobiotix, Coherus, Merck and Roche. All other authors have no competing interests.